PRENATAL THERAPY OF A PATIENT WITH VITAMIN-B12-RESPONSIVE METHYLMALONIC ACIDEMIA
PRENATAL THERAPY OF A PATIENT WITH VITAMIN-B12-RESPONSIVE METHYLMALONIC ACIDEMIA
复制标题
DOI:
10.1056/nejm197508142930701
复制
发表时间:
1975-01-01
影响因子:
158.5
通讯作者:
TANAKA, K
中科院分区:
文献类型:
--
作者:
AMPOLA, MG;MAHONEY, MJ;TANAKA, K
Methylmalonic acidemia due to deficient synthesis of 5′-deoxyadenosylcobalamin was discovered in a mid-term fetus by culture of amniotic-fluid cells. Elevated concentrations of methylmalonic acid were also found in amniotic fluid and maternal urine. Treatment during the last nine weeks of gestation with large doses of vitamin B12given to the mother reversed the increasing maternal excretion of methylmalonic acid, which was 23 μg per milligram of creatinine at 31 weeks' gestation. Just before delivery, the mother was excreting 5 μg, two to three times normal.At birth the methylmalonic acid content of the baby's urine (67μg per milligram of creatinine) and serum (2.0 μg per milliliter) was only moderately elevated, and serum vitamin B12concentration was very high. Acid levels rose in serum and urine in response to oral protein loading, but subsided after vitamin B12administration. The infant is developing normally on a restricted protein diet alone at present.Prenatal therapy of methylmalonic acidemia is possible with large amounts of vitamin B12administered to the mother.(N Engl J Med 293:313–317,1975)